In addition to well-known biomarkers of KRAS and EGFR, new genomic biomarkers, such as somatic mutations in ALK, ERBB2, TP53 have been demonstrated to be associated with lung cancer risk, response or prognosis [20], [21], [22]. The gene discussed is EGFR; the disease is lung carcinoma.